Vera Therapeutics, Inc. (VERA)
26.97
-1.13
(-4.02%)
USD |
NASDAQ |
Nov 16, 16:00
26.97
0.00 (0.00%)
After-Hours: 19:05
Vera Therapeutics Enterprise Value : 1.723B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.723B |
| November 12, 2026 | 1.791B |
| November 11, 2026 | 1.895B |
| November 10, 2026 | 1.862B |
| November 09, 2026 | 1.904B |
| November 06, 2026 | 1.844B |
| November 05, 2026 | 1.870B |
| November 04, 2026 | 2.002B |
| November 03, 2026 | 1.911B |
| November 02, 2026 | 1.878B |
| October 30, 2026 | 1.931B |
| October 29, 2026 | 1.898B |
| October 28, 2026 | 1.928B |
| October 27, 2026 | 1.859B |
| October 26, 2026 | 1.737B |
| October 23, 2026 | 1.715B |
| October 22, 2026 | 1.791B |
| October 21, 2026 | 1.947B |
| October 20, 2026 | 1.864B |
| October 19, 2026 | 1.782B |
| October 16, 2026 | 1.707B |
| October 15, 2026 | 1.757B |
| October 14, 2026 | 1.624B |
| October 13, 2026 | 1.628B |
| October 12, 2026 | 1.695B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.851B |
| October 08, 2026 | 1.841B |
| October 07, 2026 | 1.878B |
| October 06, 2026 | 1.818B |
| October 05, 2026 | 1.848B |
| October 02, 2026 | 1.890B |
| October 01, 2026 | 1.932B |
| September 30, 2026 | 2.026B |
| September 29, 2026 | 1.906B |
| September 28, 2026 | 1.915B |
| September 25, 2026 | 1.918B |
| September 24, 2026 | 1.975B |
| September 23, 2026 | 1.954B |
| September 22, 2026 | 2.185B |
| September 21, 2026 | 2.041B |
| September 18, 2026 | 2.023B |
| September 17, 2026 | 2.042B |
| September 16, 2026 | 1.862B |
| September 15, 2026 | 1.999B |
| September 14, 2026 | 2.026B |
| September 11, 2026 | 2.098B |
| September 10, 2026 | 1.994B |
| September 09, 2026 | 2.007B |
| September 08, 2026 | 2.115B |
| September 04, 2026 | 2.159B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.562B |
| Sarepta Therapeutics, Inc. | 1.897B |
| Twist Bioscience Corp. | 6.507B |
| Oncolytics Biotech, Inc. | 46.90M |
| Sangamo Therapeutics, Inc. | 40.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -93.71M |
| Revenue (Quarterly) | 10.28M |
| Total Expenses (Quarterly) | 103.99M |
| EPS Diluted (Quarterly) | -1.299 |
| Gross Profit Margin (Quarterly) | 62.84% |
| Profit Margin (Quarterly) | -911.9% |
| Earnings Yield | -21.92% |
| Normalized Earnings Yield | -21.92 |